[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postural-orthostatic-tachycardia-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postural-orthostatic-tachycardia-syndrome":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,71,96,114,137,157,182,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100510300","calgary-salt-for-pots-100510300",false,"NCT05924646","CAlgary SAlt for POTS","CAlgary SAlt for Postural Orthostatic Tachycardia Syndrome Study","CASA-POTS","Inclusion Criteria:\n\n* Physician Diagnosis of POTS as defined by the CCS Consensus Statement and as follows:\n* Sustained, excessive orthostatic tachycardia ≥ 30 bpm within 10 minutes standing.\n* Absence of orthostatic hypotension (\\>20\u002F10 mmHg decrease) within 3 minutes standing.\n* Chronic orthostatic symptoms that improve with recumbence.\n* Age 18-60 years old.\n* Ability to attend the Calgary Autonomic Research Clinic in Calgary.\n* Resident of Canada\n\nExclusion Criteria:\n\n* Overt cause for postural tachycardia (i.e., acute dehydration, thyroid disease)\n* Participants with somatization or severe anxiety symptoms will be excluded\n* Pregnant (self-reported)\n* Underlying causes of tachycardia including acute hypovolemia, endocrinopathy, anemia, anxiety, medication effects, recreational drug effects, and prolonged bedrest.\n* Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies\n* Fludrocortisone use (due to effects on renal Na+ handling)\n* Patients who have received IV saline in the 2 months preceding the study or who plan to receive it during the course of the study","ALL","18 Years","60 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","Many patients with postural orthostatic tachycardia syndrome (POTS) have decreased plasma volume. Current POTS guidelines recommend \\~10 g of salt and 2-3 L of fluid per day. Despite this recommendation, there is no long term data evaluating the use of salt in POTS. This randomized, placebo-controlled cross-over trial will evaluate a high salt diet, compared to a normal salt diet over a period of 3 months. Participants will complete 3 in lab evaluations including autonomic function testing, tilt table testing, blood volume and urine sodium evaluation, plasma catecholamine measurements and and cytokine measurements.",[28],"Postural Orthostatic Tachycardia Syndrome",[30,31,32],"Sodium","Salt","Treatment","RECRUITING","2026-04-30",{"date":36,"type":37},"2026-05-07","ACTUAL",{"date":39,"type":37},"2024-05-07",{"date":41,"type":22},"2028-12-31",{"name":43,"class":44},"University of Calgary","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":45},"100509532","nc-testing-in-lc--pots-100509532","NCT05914649","NC Testing in LC & POTS","Neurocognitive Testing in Long COVID and Postural Tachycardia Syndrome Patients With Normal Saline: A Pilot Study","Inclusion Criteria:\n\n* Patients with diagnosis of Long COVID\n* SARS-COV2 test positive\n* Symptoms \\> 12 weeks post COVID\n* Subjective complaint of 'brain fog\" or cognitive dysfunction\n* Patients with diagnosis of Postural Orthostatic Syndrome (POTS) from the Calgary Autonomic Investigation and Management Clinic\n* Subjective complaint of 'brain fog\" or cognitive impairment\n* Healthy participants\n* Without POTS or \"brain fog\"\n* Age 18 to 60 years\n* Female and Male\n* Able to give an informed consent\n\nExclusion Criteria:\n\n* Patients with overt causes for POTS (e.g., dehydration, prolonged bed rest)\n* An inability to safely withdraw from medicine(s) that could make test interpretation difficult and impossible.\n* Other factors which are in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule.\n* Unable to give an informed consent.",true,{"count":55,"type":22},100,[25],"Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Post-Acute Sequelae of COVID (PASC, or \"Long COVID\") experience cognitive dysfunction. The investigators will test the hypothesis that 999 mL of IV saline will improve cognitive function in patients with POTS and Long COVID compared to placebo (50 mL of saline).",[28,59],"Post Acute Sequelae of SARS CoV 2 Infection",[61,62,63,64],"POTS","Long COVID","Cognitive","Brain Fog",{"date":36,"type":37},{"date":67,"type":37},"2024-09-19",{"date":69,"type":22},"2030-12-31",{"name":43,"class":44},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100467189","phase-4-low-dose-naltrexone-use-in-patients-with-pots-100467189","NCT05363514","Low Dose Naltrexone Use in Patients With POTS","A Pilot Study of Low Dose Naltrexone Use in Patients With Postural Orthostatic Tachycardia Syndrome","Inclusion Criteria:\n\n* Physician diagnosis of POTS as defined by the American Autonomic Society consensus statement\n* Ability to attend research lab in Calgary, Vancouver or Hamilton, Canada\n* Not pregnant and not planning to become pregnant for the duration of the study\n* Maintain current other medications at regular doses for the duration of the study\n\nExclusion Criteria:\n\n* Overt cause for postural tachycardia (e.g. acute dehydration, hyperthyroidism)\n* Positive pregnancy test\n* Breastfeeding\n* Other factors which in the investigator's opinion would prevent participant from completing the protocol, including poor compliance during previous studies\n* Current use of Low Dose Naltrexone\n* Use of opioid containing medications or positive urine opioid test\n* History of alcohol, opioid or other substance use disorder","50 Years",{"count":80,"type":22},80,[82],"PHASE4","Many patients with Postural Orthostatic Tachycardia Syndrome (POTS) experience debilitating fatigue and this significantly impacts their daily lives. Unfortunately, there are no treatments to help POTS patients with their fatigue. One medication, called low dose naltrexone (LDN), has been tested as a treatment for fatigue in other medical conditions. In this other research, LDN helped patients feel less fatigue. Other research studies have shown that LDN can help reduce markers of inflammation called cytokines. Reducing these cytokines could help reduce symptoms as well. There have been no research studies testing LDN in POTS to date. We are planning to do a research study to test LDN as a treatment to see if it helps POTS patients feel less fatigue.",[28],[61,86,87],"LDN","Low Dose Naltrexone","NOT_YET_RECRUITING",{"date":90,"type":37},"2026-05-01",{"date":92,"type":22},"2026-07",{"date":94,"type":22},"2030-12",{"name":43,"class":44},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":45},"100430149","compression-garments-in-the-community-with-pots-100430149","NCT04881318","Compression Garments in the Community With POTS","COM-COM-POTS","Inclusion Criteria:\n\n* Physician diagnosis of Postural Tachycardia Syndrome (POTS)\n* Resident of Canada\n* Owns waist-high compression garment: medical grade or commercially available tights with a pressure rating provided (e.g. 15-18 mmHg, 20-30 mmHg, 30-40 mmHg)\n* Optional Sub-Study: owns an abdominal compression garment (e.g. abdominal shapewear, waist high shorts)\n* Able to participate in a 4-day study (2x2 day segments with a 5-day washout period)\n\nExclusion Criteria:\n\n* Overt cause for postural tachycardia (i.e., acute dehydration, thyroid disease) that precludes POTS diagnosis\n* Not a resident of Canada\n* Participants with somatization or severe anxiety symptoms will be excluded\n* Pregnant (self-reported)\n* Inability to tolerate compression garments for the duration of the study\n* Does not own a waist-high compression garment\n* Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies",{"count":104,"type":22},30,[25],"Compression Garments are a commonly prescribed treatment in Postural Orthostatic Tachycardia Syndrome (POTS). The effectiveness of a proof-of-concept compression garment has been demonstrated in an acute laboratory setting. It is not known if commercially available compression garments that participants wear in their every day lives are effective at improving heart rate and reducing symptoms in POTS. This trial will evaluate the use of commercially available waist-high and abdominal compression garments in adults diagnosed with POTS in a community setting.",[28],{"date":36,"type":37},{"date":110,"type":37},"2021-05-17",{"date":112,"type":22},"2026-12-31",{"name":43,"class":44},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":121,"maxAge":18,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":45},"100487944","postural-sway-and-counterpressure-maneuvers-for-pediatric-syncope-100487944","NCT05633693","Postural Sway and Counterpressure Maneuvers for Pediatric Syncope","Impact of Postural Sway on Cardiovascular Control in Pediatric Patients With Syncope","Inclusion Criteria:\n\nWe are looking for English speaking pediatric patients aged 6-18 years with a diagnosis of recurrent fainting (at least two episodes of fainting with loss of consciousness or near loss of consciousness in the last year) of a vasovagal origin or associated with the postural orthostatic tachycardia syndrome (POTS) (as determined by a paediatric cardiologist) to take part in this study.\n\nExclusion Criteria:\n\nThose with a diagnosis of recurrent fainting accompanied by any of the following will not be eligible to take part:\n\nKnown history of:\n\n* Suspected or confirmed cardiac arrhythmia (e.g., Wolff-Parkinson-White, Long QT)\n* Traumatic head injury\n* New presentation of a seizure disorder OR epilepsy recurrence\n* Overdose or intoxication\n* Structural heart disease\n* Cardiovascular disease including hypertension, diabetes, or renal disease\n* Hypoglycemia\n* Physical and\u002For psychological disability that impact their ability to complete the tests\n\nFemale participants of childbearing age will be excluded if they are pregnant, or think they might be. Participants who are taking any cardiovascular acting medications, including treatment for cardiovascular disease, or medications for orthostatic syncope (e.g. fludrocortisone, slow-release sodium chloride, β-blockers, midodrine) will be excluded from the study.\n\nIn order to reduce the likelihood of transmission of COVID-19, participants will only be eligible to participate in the study if they have received full immunisation against COVID-19 according to current Health Canada guidelines. Accordingly, participants will be asked to provide evidence of their vaccination status in order to take part in the study.","6 Years",{"count":104,"type":22},[25],"The investigators are interested in whether discrete counterpressure maneuvers, or muscle movements in the lower body, will boost blood pressure and cardiovascular control in children who faint. We will record cardiovascular responses to maneuvers of exaggerated sway, leg crossing, crouching, and gluteal muscle tensing in children who faint (N=20), as well as their height, weight, muscularity, and pubertal (Tanner) stage. Autonomic cardiovascular control will be measured using a Valsalva manoeuvre (expiration against a closed airway for 20 seconds) and a supine-stand test. The primary outcomes are noninvasive measures of cardiovascular responses to the maneuvers (blood pressure, cerebral blood flow, and stroke volume (volume of blood pumped per heartbeat). Comparisons will be made across levels of sex, diagnosis, Tanner stage, muscularity, height, and degree of autonomic control.",[126,28,127],"Syncope, Vasovagal","Orthostatic Intolerance","2026-04-22",{"date":130,"type":37},"2026-04-23",{"date":132,"type":37},"2023-04-17",{"date":134,"type":22},"2027-06",{"name":136,"class":44},"Simon Fraser University",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":121,"maxAge":18,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":45},"100481957","paediatric-syncope-in-the-emergency-department-100481957","NCT05555771","Paediatric Syncope in the Emergency Department","Determining the Effectiveness of Counterpressure Maneuvers in Pediatric Patients Presenting With Syncope to the Emergency Department","DETECT-ED","Inclusion Criteria:\n\n1. Those between the ages of 6-18 years (inclusive)\n2. Presenting to the ED daily 1000-2200 with resolved transient loss of consciousness that has occurred within the last week\n3. Able to complete the survey in English\n4. Willing and able to provide consent and assent\n\nExclusion Criteria:\n\n1. Those with a known history of any of the following:\n\n   * Suspected or confirmed cardiac arrhythmia diagnosis (e.g., Wolff-Parkinson-White, long QT)\n   * Traumatic head injury\n   * New presentation of seizure disorder\n   * Epilepsy recurrence\n   * Overdose, intoxication\n   * Structural heart disease\n2. Patients with hypoglycaemia and who are psychogenic with vasovagal syncope who do not present with prodromal symptoms\n3. Previously enrolled in this study",{"count":146,"type":22},300,[25],"The investigators will assess the efficacy of clinically recommended counterpressure maneuvers (CPM) in preventing syncope for paediatric patients. Participants presenting to the emergency department (ED) will first provide written informed consent. In stage I, they will be asked to complete a brief survey documenting the presentation of their syncopal episode, and any prodromal symptoms they experienced. Participants that consent to the second stage of the study will either receive usual care (control arm) or training in counter pressure maneuvers alongside usual care (intervention arm; leg crossing, bending, arm tensing). These patients will be followed for one years time, and will be asked to complete monthly surveys detailing their syncopal and presyncopal recurrence. Medical records will be accessed over the duration of the study to identify any changes in medical diagnosis.",[126,28,127],{"date":130,"type":37},{"date":152,"type":37},"2022-09-03",{"date":154,"type":22},"2027-09-30",{"name":156,"class":44},"Dr. Victoria Claydon",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":164,"maxAge":18,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":180,"locationsCount":45},"100455558","auricular-vagal-nerve-stimulation-for-hypermobile-ehlers-danlos-syndrome-100455558","NCT05212129","Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome","Hypermobile Ehlers-Danlos Syndrome: Efficacy of Non-invasive Vagal Nerve Stimulation and Effects on Brain-Gut Physiology","Inclusion Criteria:\n\n* Children aged 10-18 years old\n* Children with functional upper GI complaints and clinical suspicion for hEDS or HSD as well as a Beighton score of at least 4\u002F9\n* Children with functional upper GI complaints and clinical suspicion for ANS dysfunction\n* De-identified data from our prior studies (IRB #689519 and IRB #1064187) of patients with functional GI disorders who do NOT meet criteria for hEDS will be used as a comparison group\n* Children who are English-speaking and lack other explanation for symptoms\n* Children willing to participate and consent to this study (for children, have a parent willing to participate)\n\nExclusion Criteria:\n\nA) Exclusion Criteria applying to all participants:\n\n* Medically complex children or those who take a medication or suffer from a disease that can explain symptoms will be excluded from participation in the study.\n* Adult subjects, children or their parents who have significant developmental delay (will be excluded due to difficulties in accurately completing the questionnaires and assessing symptoms)\n* Patients with findings of organic disease such as peptic ulcer disease, H.pylori gastritis, celiac disease, inflammatory bowel disease, allergic disorders, metabolic disorder or any other chronic condition or medication that may cause chronic GI symptoms will be excluded from the study.\n* Patients who are treated with a new drug affecting the central nervous system in the two weeks prior to enrollment will also be excluded.\n* Pregnancy (evaluating MD screens patients as they normally would during a clinic visit (by questioning) and would only perform urine pregnancy test if clinically indicated (absence of menstrual period or other symptoms concerning for pregnancy)\n* Chronic alcohol\u002Fillicit drug use and\u002For smoking.\n\nB) Exclusion Criteria for subjects undergoing pVNS therapy:\n\n* Severe dermatological condition or active infection of external or middle ear\n* Implanted electrical device\n\nC) Exclusion Criteria for subjects undergoing aVNS therapy:\n\n* Hearing impaired\n* Sight impaired without correction\n* Seizure disorder\n\nD) Exclusion Criteria for subjects undergoing gastric motor function sub-study:\n\n* Patients with pacemakers, metal clips used in previous surgery or other device which are not compatible with MRI scanning\n* Claustrophobia or inability to lie still in the scanner\n* Orthodontic braces or permanent retainers\n* Patients who are unable to tolerate noise produced by the MRI\n* Egg allergy or anticipated inability to complete a standardized egg meal\n\nE) Exclusion Criteria for subjects undergoing HepGI Biobank specimen collection sub-study:\n\n* Bleeding disorder for the specific biopsies\n* Recent antibiotic usage for fecal sample\n* Significant anemia or clinical status which will not allow safe blood draw required for blood collection\n* Refusal of blood collection or to provide DNA sample\n* Inability or unwillingness on the individual (or parent\u002Flegal guardian) to provide clinical or family history.","10 Years",{"count":166,"type":22},90,[25],"Hypermobile Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder characterized by hyperextensible skin, joint hypermobility and additional connective tissue manifestations. For unclear reasons, hEDS is associated with many gastrointestinal (GI) and autonomic nervous system (ANS) complaints such as postural orthostatic tachycardia syndrome (POTS). This study will address the clinical relationship between hEDS\u002FHypermobile Spectrum Disorders and autonomic regulation and see if there is a benefit of two forms of non-invasive vagal nerve stimulation therapies to reduce GI symptoms in hEDS and POTS. The study will also investigate plausible effects of these nerve stimulation therapies on gastric function and autonomic signaling.",[170,171,28,172,173],"Functional Gastrointestinal Disorders","Hypermobile Ehlers-Danlos Syndrome","Autonomic Nervous System Disease","Autonomic Nervous System Imbalance","2026-02-11",{"date":176,"type":37},"2026-02-13",{"date":178,"type":37},"2021-04-05",{"date":112,"type":22},{"name":181,"class":44},"Medical College of Wisconsin",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":53,"sex":17,"minAge":189,"maxAge":4,"enrollmentInfo":190,"targetDuration":192,"studyType":193,"phases":4,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":45},"100538535","phenotyping-of-postural-orthostatic-tachycardia-syndrome-pots-100538535","NCT06292104","Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS)","Multimodality Deep Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS), Aim 1","Inclusion Criteria:\n\nPOTS Patients\n\n* Age ≥ 14 years, able to provide informed consent (assent with parental consent for age \\\u003C 18) and comply with procedures\n* Meets consensus criteria for POTS: (1) sustained increase in heart rate ≥ 30 bpm above supine baseline within 10 min of quiet standing or upright tilt (≥ 40 bpm in individuals 12 to 19 years of age) OR sustained upright HR (heart rate) \\>120 bpm, (2) absence of orthostatic hypotension, (3) symptoms with standing that improve with sitting or lying down, (4) resting supine heart rate \\\u003C 100 bpm, (5) orthostatic symptoms present for at least 6 months\n* Stable oral medication regimen for at least 14 days\n\nNon-POTS Control Patients\n\n* Healthy women, age 18 - 30 years, able to provide informed consent and comply with study procedures\n* Does NOT meet consensus criteria for postural tachycardia syndrome\n* No symptoms of orthostatic intolerance or dysautonomia. No history of other major medical disorder\n* Resting supine heart rate \\\u003C 100 bpm\n\nExclusion Criteria:\n\nNone of the following exclusion criteria:\n\n* Use of amphetamine-type stimulants, diuretics, selective norepinephrine reuptake inhibitor, anticholinergic medications (including tricyclic antidepressant medications), fludrocortisone, desmopressin in past 14 days\n* Use of other autonomic drugs (adrenergic agents, pyridostigmine, droxidopa, triptans, ivabradine) in past 48 hours\n* Currently receiving IVIG (Intravenous immunoglobulin), subcutaneous IgG (Immunoglobulin G), or any investigational medication (in past year)\n* Infusion of iv fluids in past 7 days\n* History or evidence of another condition explaining symptoms or orthostatic tachycardia (e.g. structural heart disease, CSF (Cerebrospinal fluid) hypovolemia, or severe traumatic brain injury)","14 Years",{"count":191,"type":22},350,"1 Year","OBSERVATIONAL","This is an observational study to deeply phenotype the disorder of POTS using multiple testing modalities.",[28],"2025-06-23",{"date":198,"type":37},"2025-06-27",{"date":200,"type":37},"2024-03-05",{"date":202,"type":22},"2029-01",{"name":204,"class":44},"University of Texas Southwestern Medical Center",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":23,"phases":213,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":45},"100496198","the-long-covid-19-wearable-device-study-100496198","NCT05741112","The Long COVID-19 Wearable Device Study","Inclusion Criteria:\n\n* Is at least 18 years old.\n* Has a self\u002Fand or physician diagnosis of:\n* Long COVID (based on the WHO working definition),\n* ME\u002FCFS (myalgic encephalomyelitis \u002F chronic fatigue syndrome, self-diagnosis based on IOM criteria), and\u002For\n* POTS (Postural Orthostatic Tachycardia Syndrome).\n* Is interested in tools to manage ME\u002FCFS, POTS, and\u002For Long COVID symptoms.\n* Owns a wearable device they are willing to use for this study or does not own a device and agrees to utilize a study-provided one.\n* Agrees to wear the device throughout the study period, share the data with the study, and sync data at least weekly.\n* Has access to a smartphone or tablet to enable syncing wearable data and viewing device feedback.\n* Agrees to disclose involvement in other ME\u002FCFS, POTS, and\u002For Long COVID interventions such as medical treatment, self-management, and other interventional studies.\n* Agrees to complete at least 75% of the study surveys.\n\nExclusion Criteria:\n\n* As long as they meet inclusion there is no exclusion",{"count":212,"type":22},100500,[25],"To further characterize Long COVID-19 by collecting data from individuals who already own wearable devices or are provided with a wearable device along with basic and enhanced educational materials to determine if both can improve Long COVID-19 symptom management and post-exertional malaise.",[62,28,216,217,218,219],"Dysautonomia","Myalgic Encephalomyelitis","Chronic Fatigue Syndrome","Long Covid19","2025-05-09",{"date":222,"type":37},"2025-05-11",{"date":224,"type":37},"2023-11-16",{"date":226,"type":22},"2025-12-01",{"name":228,"class":44},"Scripps Translational Science Institute"]